Abivax SA Establishes Equity Offering Program with Piper Sandler
Ticker: AAVXF · Form: 6-K · Filed: Nov 19, 2024 · CIK: 1956827
| Field | Detail |
|---|---|
| Company | Abivax S.A. (AAVXF) |
| Form Type | 6-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $150.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-offering, financing, at-the-market
TL;DR
Abivax is setting up a program to sell its ADSs via Piper Sandler to raise cash as needed.
AI Summary
On November 19, 2024, Abivax SA entered into an Equity Distribution Agreement with Piper Sandler & Co. to establish an equity offering program. Under this program, Abivax may offer and sell its American Depositary Shares (ADS), representing ordinary shares, from time to time through Piper Sandler acting as its sales agent.
Why It Matters
This agreement allows Abivax to raise capital opportunistically by selling its shares, which can be used for funding operations, research, or strategic initiatives.
Risk Assessment
Risk Level: medium — Equity offering programs can dilute existing shareholders and signal potential cash needs, but also provide flexibility for funding.
Key Players & Entities
- Abivax SA (company) — Registrant and issuer of ADSs
- Piper Sandler & Co. (company) — Sales agent for the equity offering
- November 19, 2024 (date) — Date of the Equity Distribution Agreement
FAQ
What is the purpose of the Equity Distribution Agreement between Abivax SA and Piper Sandler & Co.?
The agreement establishes an equity offering program under which Abivax SA may offer and sell its American Depositary Shares (ADS) from time to time through Piper Sandler & Co. as its sales agent.
What type of securities can Abivax SA offer and sell under this program?
Abivax SA may offer and sell American Depositary Shares (ADS), with each ADS representing one ordinary share.
Who is acting as the sales agent for Abivax SA in this equity offering program?
Piper Sandler & Co. is acting as the sales agent for Abivax SA.
When was the Equity Distribution Agreement entered into?
The Equity Distribution Agreement was entered into on November 19, 2024.
What is the filing form used by Abivax SA for this announcement?
Abivax SA filed a Form 6-K report with the SEC.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-11-19 16:43:55
Key Financial Figures
- $150.0 million — ng an aggregate offering price of up to $150.0 million (subject to French regulatory limits).
Filing Documents
- d862454d6k.htm (6-K) — 13KB
- d862454dex991.htm (EX-99.1) — 25KB
- g862454g1119030548984.jpg (GRAPHIC) — 3KB
- 0001193125-24-261777.txt ( ) — 42KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Abivax SA (Registrant) Date: November 19, 2024 /s/ Marc de Garidel Marc de Garidel Chief Executive Officer